New combo therapy aims to boost liver cancer treatment
NCT ID NCT07246668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a precise type of radiation (carbon ion radiotherapy) to standard immunotherapy drugs (atezolizumab and bevacizumab) can better control advanced liver cancer. About 52 adults with liver cancer that cannot be surgically removed will receive this combination. The goal is to see if the radiation helps shrink tumors and improve survival compared to drugs alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••